Proteomics

Dataset Information

0

Non-metabolic PHGDH facilitates cMyc to urge advanced liver cancer


ABSTRACT: Metabolic dysregulation is an important feature of malignant tumors. Serine synthesis pathway (SSP) reshapes tumor cells to enhance their growth and survival capabilities, especially under serine starvation. However, whether and how SSP is involved in the progression of liver cancer has not been clearly stated. We applied a combination of quantitative proteomics and transcriptomics and discovered the increased expression of PHGDH and PSAT1 in mice liver cancer induced by SB. PHGDH is the first rating-limited enzyme of SSP and the conditional knockout of PHGDH in liver impaired the advanced liver cancer formation. However, the specific inhibition of enzymatic activity of PHGDH in liver has no obvious suppressive effect on advanced liver cancer. Further, we explored a non-metabolic function of PHGDH, which used its ACT domain to bind and regulate cMyc transcriptional activity, then selectively activated genes expression of Lcn2, Got1, Fabp5 and Psat1, indicating PHGDH drives/links multiple metabolic pathways and augmented its function through its non-metabolic role. In addition, the mutant p53 would release the suppression of PHGDH in mice liver cancer model and clinical liver cancer samples. Hence, the mutant p53/PHGDH/cMyc axis could be a potential target to cure advanced liver cancer.

INSTRUMENT(S): Orbitrap Fusion

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Hepatocyte, Liver

DISEASE(S): Liver Cancer

SUBMITTER: zhu sam  

LAB HEAD: Xiongjun Wang

PROVIDER: PXD017809 | Pride | 2023-07-20

REPOSITORIES: Pride

altmetric image

Publications

Elevated Nuclear PHGDH Synergistically Functions with cMyc to Reshape the Immune Microenvironment of Liver Cancer.

Zhu Hongwen H   Yu Hua H   Zhou Hu H   Zhu Wencheng W   Wang Xiongjun X  

Advanced science (Weinheim, Baden-Wurttemberg, Germany) 20230420 17


Herein, we observed that nuclear localization of phosphoglycerate dehydrogenase (PHGDH) is associated with poor prognosis in liver cancer, and Phgdh is required for liver cancer progression in a mouse model. Unexpectedly, impairment of Phgdh enzyme activity exerts a slight effect in a liver cancer model. In liver cancer cells, the aspartate kinase-chorismate mutase-tyrA prephenate dehydrogenase (ACT) domain of PHGDH binds nuclear cMyc to form a transactivation axis, PHGDH/p300/cMyc/AF9, which dr  ...[more]

Similar Datasets

2021-01-04 | PXD023142 | Pride
2010-04-19 | E-GEOD-20085 | biostudies-arrayexpress
2021-01-29 | GSE165684 | GEO
2010-04-19 | GSE20085 | GEO
2021-11-04 | GSE144506 | GEO
2022-03-30 | GSE198380 | GEO
2024-02-01 | GSE248632 | GEO
2024-02-01 | GSE248633 | GEO
2024-04-23 | GSE173270 | GEO
2021-10-07 | GSE185312 | GEO